Artiva Biotherapeutics Expands Leadership Team
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), a pioneering clinical-stage biotechnology firm, is excited to announce the recent appointment of Dr. Subhashis Banerjee, M.D., as the Chief Medical Officer. With an impressive history of over 20 years in clinical development specifically focused on autoimmune diseases, Dr. Banerjee's arrival is set to enhance Artiva's mission of delivering effective, safe, and accessible cell therapies.
Dr. Banerjee's Background in Medical Research
Dr. Banerjee, a seasoned rheumatologist and immunologist, brings a wealth of experience from his previous role as Disease Area Head at Bristol Myers Squibb (BMS), as well as his tenure at VYNE Therapeutics. His expertise will be invaluable as Artiva advances its AlloNK® program aimed at addressing B-cell driven autoimmune conditions.
With a profound background in the clinical development of therapies targeting autoimmune diseases, Dr. Banerjee takes over from Dr. Thorsten Graef, M.D., Ph.D. Dr. Graef will continue his contributions to Artiva in a strategic advisor capacity, ensuring a smooth transition while maintaining the company's momentum in developing innovative treatments.
Strategic Vision for AlloNK® Development
“We're thrilled to welcome Dr. Banerjee to the Artiva team as we intensify our clinical focus,” said Fred Aslan, M.D., the CEO of Artiva. “His track record, including the development of leading treatments like Humira® and Orencia®, aligns perfectly with our goals for AlloNK®, which aims to revolutionize the treatment landscape for autoimmune diseases.”
Dr. Banerjee emphasized the potential of AlloNK® in transforming patient outcomes in autoimmune disorders. His vision includes leveraging the robust B-cell depletion capacity of AlloNK® as an effective solution for conditions like systemic lupus erythematosus (SLE). The innovative NK cell-focused approach represents a significant leap toward offering safe and accessible long-term therapy.
A Seasoned Team to Drive Innovation
Artiva's strategic hiring of skilled professionals doesn't end with Dr. Banerjee. The leadership team now includes esteemed additions such as David Moriarty, Ph.D., as SVP of Clinical Operations, and Benjamin Dewees as SVP of Regulatory Affairs. Each of these individuals brings decades of expertise that enhance Artiva's operational capabilities in the fast-evolving arena of biotechnology.
These strategic hires reflect Artiva's commitment to building a well-rounded team capable of navigating the complex landscape of autoimmune conditions and cell therapies. Dr. Moriarty's extensive clinical research background, paired with Mr. Dewees' regulatory affairs experience, underscores the organization's dedication to advancing AlloNK® effectively.
About Artiva Biotherapeutics
Founded in 2019 and headquartered in San Diego, Artiva strives to create breakthrough therapies for some of the most challenging autoimmune diseases and cancers. The AlloNK® program, which is currently undergoing clinical evaluation, stands as Artiva's flagship initiative. It represents a new frontier in non-genetically modified NK cell therapy for extensive B-cell depletion. This ambitious program aims to address multiple autoimmune conditions with a focus on patient accessibility and safety.
Artiva's pipeline also features CAR-NK candidates that target solid and hematologic cancers. This ambition was bolstered by a partnership with GC Cell, based in South Korea, enabling Artiva to leverage advanced NK cell manufacturing technologies.
Frequently Asked Questions
What is Artiva Biotherapeutics' primary mission?
Artiva Biotherapeutics aims to develop effective and accessible cell therapies for patients suffering from autoimmune diseases and cancers.
Who is the new Chief Medical Officer of Artiva?
Dr. Subhashis Banerjee has been appointed as the Chief Medical Officer, bringing extensive experience in autoimmune disease research and development.
What is the AlloNK® program?
AlloNK® is an allogeneic NK cell therapy designed to increase the effectiveness of monoclonal antibodies in treating B-cell driven autoimmune diseases.
What recent leadership changes have occurred at Artiva Biotherapeutics?
Artiva has strengthened its leadership team with the appointments of Dr. Banerjee as CMO, David Moriarty, Ph.D. as SVP of Clinical Operations, and Benjamin Dewees as SVP of Regulatory Affairs.
Where is Artiva Biotherapeutics located?
Artiva Biotherapeutics is headquartered in San Diego, California, positioning itself in a vibrant biotech environment.
